(“HSI”) focuses on the needs and clinical outcomes of patients with headache disorders.
-HSI has developed objective, innovative, non-invasive electroencephalogram (“EEG”) tests, leveraging machine learning to diagnose and monitor migraine with the intent to expand to other headache disorders.
-The Company has developed quantitative tests, and provide an objective direct measure of brain activity that are non-falsifiable.
-The Company plans to offer various types of tests, each having its own specific set of values to stakeholders. These include: non-emergency diagnosis on non-pain days, diagnosing a headache in-progress, monitoring for improvement or deterioration, disability assessment andcseverity assessment.
• These tests will provide value to patients, neurologists, pain specialists, neurosurgeons, emergency and urgent care doctors, researchers, insurers, public health and public health policy planners and the pharmaceutical industry.
